The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Concerns about bird flu are growing among health officials weeks after the first person in the U.S. died from the virus, and ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

The Stargate Initiative, spearheaded by several tech giants, has raised alarm in the most paranoid parts of the MAGA movement ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

The Trump Administration’s abrupt cancellation of National Institutes of Health meetings and grant reviews has sparked ...

Last Friday, HHS announced it will provide approximately $590 million to Moderna to accelerate the development of mRNA-based ...